Methods of performing vagal-induced asystole
AssigneeEmory University
InventorJohn D. Puskas
Life of this patent
Estimating the term…
Abstract
A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating the vagus nerve. Disclosed embodiments include positioning one or more electrodes in the esophagus, trachea, or jugular vein, on the neck of the patient, and combinations thereof.
Claims144
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting an electrode into the esophagus of said patient;
- and
- actuating said electrode to create an electrical field effective to stimulate said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting an electrode into the trachea of said patient;
- and
- actuating said electrode to create an electrical field effective to stimulate said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting an electrode into the jugular vein of said patient;
- and
- actuating said electrode to create an electrical field effective to stimulate said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- positioning an electrode on the neck of said patient;
- and
- actuating said electrode to create an electrical field effective to stimulate said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into the esophagus of said patient;
- inserting a second electrode into the trachea of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into the esophagus of said patient;
- inserting a second electrode into a jugular vein of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into the esophagus of said patient;
- placing a second electrode on the neck of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into the trachea of said patient;
- inserting a second electrode into a jugular vein of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into the trachea of said patient;
- placing a second electrode on the neck of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
A method of performing vagal-induced asystole in a patient comprising the steps of:
- administering an amount of a pharmaceutical composition effective to produce cardiac asystole upon stimulation of one or both vagus nerves;
- inserting a first electrode into a jugular vein of said patient;
- placing a second electrode on the neck of said patient;
- and
- actuating at least one of said electrodes to create an electrical field which stimulates said vagus nerve;
- wherein the pharmaceutical composition comprises an acetylcholinesterase inhibitor, a β-adrenergic receptor blocker, and a calcium channel blocker.
Dependencies are inferred from the claim text.